SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-009031
Filing Date
2022-05-10
Accepted
2022-05-10 16:41:10
Documents
58
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q virx-20220331.htm   iXBRL 10-Q 2345257
2 EX-31.1 virx-ex31_1.htm EX-31.1 13307
3 EX-31.2 virx-ex31_2.htm EX-31.2 13289
4 EX-32.1 virx-ex32_1.htm EX-32.1 6152
5 EX-32.2 virx-ex32_2.htm EX-32.2 6062
  Complete submission text file 0000950170-22-009031.txt   7428829

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT virx-20220331.xsd EX-101.SCH 57662
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT virx-20220331_pre.xml EX-101.PRE 359059
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT virx-20220331_def.xml EX-101.DEF 253293
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT virx-20220331_cal.xml EX-101.CAL 36800
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT virx-20220331_lab.xml EX-101.LAB 464756
52 EXTRACTED XBRL INSTANCE DOCUMENT virx-20220331_htm.xml XML 1002213
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51531 | Film No.: 22910511
SIC: 2834 Pharmaceutical Preparations